Wells Fargo Maintains Overweight on Rapport Therapeutics, Lowers Price Target to $47

Benzinga · 1d ago
Wells Fargo analyst Benjamin Burnett maintains Rapport Therapeutics (NASDAQ:RAPP) with a Overweight and lowers the price target from $50 to $47.